Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma.

Leanne Kaye Vy Thao VuongMeredith A BarrettElroy BoersTheresa Guilbert

Published in: NPJ primary care respiratory medicine (2022)

Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medication use and may reduce symptom-related disruptions.

Keyphrases

healthcare
chronic obstructive pulmonary disease
mental health
climate change
lung function
cystic fibrosis
allergic rhinitis